ING Group’s Neurocrine Biosciences NBIX Stock Holding History

ING Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11,300	Closed	-$1.49M	–	596
2023 Q4	$1.49M	Buy	+11,300	New	+$1.3M	0.01%	442

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ING Group's NBIX Position: Q1 2024 in Review

ING Group sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 11,300 shares — an estimated $1.49M sold.

ING Group first reported a position in NBIX in Q4 2023 and held it in 1 quarter. The position peaked at $1.49M in Q4 2023. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

ING Group reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
ING Group sold 11,300 Neurocrine Biosciences shares in Q1 2024, an estimated $1.49M.
ING Group first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 1 quarter.
ING Group's Neurocrine Biosciences position peaked at $1.49M in Q4 2023.
589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on ING Group's 13F filing for Q1 2024, filed 10 May 2024.